12 assets in Penile Carcinoma

Therapeutic assets addressing Penile Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Penile Carcinoma	National Cancer Institute (NCI)	P2	B (60)
Cyclophosphamide Penile Carcinoma	HRYZ Biotech Co.	P2	B (60)
Nivolumab Penile Carcinoma	National Cancer Institute (NCI)	P2	B (60)
Ipilimumab Penile Carcinoma	National Cancer Institute (NCI)	P2	B (59)
Pembrolizumab Penile Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Cis-Diamminedichloroplatinum Ii Penile Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Elimusertib Penile Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Fludarabine Penile Carcinoma	HRYZ Biotech Co.	P1	CC (43)
Fludeoxyglucose Penile Carcinoma	Jonsson Comprehensive Cancer Center	P1	CC (43)
Hryz-T101 Penile Carcinoma	HRYZ Biotech Co.	P1	CC (43)
Hryz-T101 Tcr-T Cell Penile Carcinoma	HRYZ Biotech Co.	P1	CC (43)
Somatotropin (Ox), 127-L-Leucine- Penile Carcinoma	German Cancer Research Center	P1	CC (43)